Welcome to our dedicated page for Elicio Therapeutics SEC filings (Ticker: ELTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Elicio Therapeutics filings document the regulatory record of a Nasdaq-listed clinical-stage biotechnology company focused on cancer immunotherapies. Its disclosures cover common stock registered on The Nasdaq Capital Market, emerging growth company reporting status, operating and financial results, corporate updates, and material-event reports.
Recent filings also address capital-structure matters, including an at-the-market equity program tied to a Form S-3 registration statement, as well as Regulation FD and other event disclosures for ELI-002, AMPLIFY-7P, AMPLIFY-201, mKRAS-specific T cell response data, scientific publications, governance matters, shareholder voting topics, and risk-related clinical and regulatory updates.
Elicio Therapeutics (ELTX) filed an 8-K announcing financial results for the quarter ended September 30, 2025 and providing corporate updates. The company furnished a press release as Exhibit 99.1 with additional details.
The information furnished, including Exhibit 99.1, is not deemed “filed” under Section 18 of the Exchange Act and is not incorporated by reference unless expressly stated.
Actyus Private Equity SGIIC, S.A. filed a Schedule 13G/A reporting beneficial ownership of 268,564 shares of Elicio Therapeutics, Inc. common stock, representing 1.64% of the class. The percentage was calculated using 16,338,284 shares outstanding as of 08/05/2025, per the company’s Form 10-Q. Actyus states the shares are held by NAVIS VB FUND I and that it acts as the fund’s management company. The filer certifies the shares were not acquired to change or influence control of the issuer and discloses sole voting and dispositive power over the reported shares.
Elicio Therapeutics, Inc. (ELTX) filed a Form 8-K reporting a material event and included three exhibits: a press release dated September 17, 2025, a corporate presentation dated September 17, 2025, and the AMPLIFY-7P trial attachment listed as Exhibit 99.2. The filing references T‑cell response metrics related to mKRAS (including T cell response rate, average and median fold change, and thresholds correlating with clinical activity) and notes the inclusion of CD4+ and CD8+ responses as well as responses to seven mKRAS antigens and patient tumor antigens. The document is signed by Robert Connelly, President and Chief Executive Officer.
The filing supplies named exhibits that investors can review for trial details and corporate messaging; the 8-K itself does not disclose additional numerical trial outcomes in the provided excerpt, so readers should consult the attached press release, presentation, and Exhibit 99.2 for complete data.
Elicio Therapeutics reported that follow-up data from its Phase 1 AMPLIFY-201 study of ELI-002 were published in the peer-reviewed journal Nature Medicine. The company issued a press release announcing the publication, which is attached to this report as Exhibit 99.1 and incorporated by reference. The filing identifies the company as a Delaware corporation with common stock trading under the ticker ELTX on The Nasdaq Capital Market. This disclosure is limited to the publication notice and the inclusion of the press release as an exhibit; no financial results, trial outcomes, or operational actions are presented within the report.